FDA commissioner touts real-time trial monitoring to cut drug development dead time

The Food and Drug Administration announced a new approach that will let regulators view clinical trial endpoints as they happen, using cloud‑based data streams.

The move targets the long delays that typically add up to a decade before a drug reaches market. FDA data shows that about 45% of the time from a Phase 1 trial to final submission is spent in idle periods with no active trial data.

Commissioner Marty Makary argues that real‑time monitoring can shrink this dead time, enabling continuous trials without compromising safety. He sees the change as a step toward faster patient access to effective therapies.

Makary, a former surgical oncologist, emphasizes that modern technology can challenge the assumption that new cures must endure lengthy waits before reaching patients.